Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunder Biomedical Tech CoROCO:4115 58 EV-to-EBIT is 63.35 as of Sep. 03, 2026, which is 260% above its 10-year median of 17.59. GuruFocus rates ROCO:4115 with a GF Score™ of 58/100 and a GF Value™ of NT$9.37 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 474 Medical Devices & Instruments companies, Sunder Biomedical Tech Co ranks worse than 88.19% on this metric.
The historical rank and industry rank for Sunder Biomedical Tech Co's EV-to-EBIT or its related term are showing as below:
ROCO:4115'
s EV-to-EBIT Range Over the Past 10 Years
Min: -54.79 Med: 17.59 Max: 66.66
Current: 63.34
During the past 8 years, the highest EV-to-EBIT of Sunder Biomedical Tech Co was 66.66. The lowest was -54.79. And the median was 17.59.
ROCO:4115's EV-to-EBIT is ranked worse than 88.19% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 18.76
vs ROCO:4115: 63.34
Sunder Biomedical Tech Co (ROCO:4115) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Sunder Biomedical Tech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$751.3 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunder Biomedical Tech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunder Biomedical Tech Co EV-to-EBIT Related Terms
Sunder Biomedical Tech Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4115 vs ISRG, BDX, RMD: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, Sunder Biomedical Tech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunder Biomedical Tech Co EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sunder Biomedical Tech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Sunder Biomedical Tech Co's EV-to-EBIT falls into.
Sunder Biomedical Tech Co's current Enterprise Value is NT$724.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sunder Biomedical Tech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$11.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunder Biomedical Tech Co (ROCO:4115) has a EV-to-EBIT of 63.35 as of Sep. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunder Biomedical Tech Co and its competitors. This is 260% above median its historical median of 17.59. According to the industry distribution chart, Sunder Biomedical Tech Co ranks #418 out of 474 companies in the Medical Devices & Instruments industry, placing it in the top 88.2%.
Is Sunder Biomedical Tech Co's EV-to-EBIT too high?
Sunder Biomedical Tech Co's current EV-to-EBIT of 63.35 is 260% above median its 10-year median of 17.59. The Medical Devices & Instruments industry median EV-to-EBIT is 18.76. Sunder Biomedical Tech Co's value of 63.35 is 237.7% above this industry median. Based on the distribution chart, Sunder Biomedical Tech Co ranks #418 out of 474 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sunder Biomedical Tech Co has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunder Biomedical Tech Co's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sunder Biomedical Tech Co ranks #418 out of 474 companies for EV-to-EBIT. This places Sunder Biomedical Tech Co in the lower half of its industry. The industry median EV-to-EBIT is 18.76. Sunder Biomedical Tech Co's value of 63.35 is 237.7% above this benchmark. While the company's 10-year median is 17.59 vs. the industry median of 18.76, Sunder Biomedical Tech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.76, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunder Biomedical Tech Co's current EV-to-EBIT of 63.35 is 237.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Sunder Biomedical Tech Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunder Biomedical Tech Co's current EV-to-EBIT is 63.35, which is 260% above median its own 10-year median of 17.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunder Biomedical Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co (ROCO:4115) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$9.37, compared to a current price of NT$7.29 — trading 22.2% below its estimated fair value. The current EV-to-EBIT is 63.35, which is 260% above median its 10-year median of 17.59 and 237.7% above the Medical Devices & Instruments industry median of 18.76. Sunder Biomedical Tech Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Sunder Biomedical Tech Co (ROCO:4115), the current EV-to-EBIT is 63.35 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunder Biomedical Tech Co (ROCO:4115) Overvalued in 2026?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co stock appears to be undervalued.
The current stock price of NT$7.29 is trading 22.2% below its estimated GF Value™ of NT$9.37.
GuruFocus considers Sunder Biomedical Tech Co to be Modestly Undervalued.
Key valuation signals for ROCO:4115:
EV-to-EBIT: 63.35 (260% above median its 10-year median of 17.59)
GF Value™: NT$9.37 vs. price of NT$7.29 (22.2% below fair value)
Industry Position: 237.7% above the Medical Devices & Instruments median (#418 of 474)
No single metric tells the full story. See the ROCO:4115 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.
58GF Score
Get the complete analysis for ROCO:4115
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4115 has been successfully added to your 
